Stereotactic Radioablation for Stereotactic Radioablation for Ventricular Tachycardia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Stereotactic Radioablation for Ventricular TachycardiaStereotactic Radioablation - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial demonstrates that STAR ablation is a safe and feasible option for cardiomyopathy patients with refractory ventricular tachycardia.

Eligible Conditions
  • Stereotactic Radioablation for Ventricular Tachycardia

Treatment Effectiveness

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 6 month period before treatment to the 6 month period after ablation with a 6 week blanking period post-treatment.

Month 6
Efficacy of radiation treatment for VT reduction
90 days after treatment
Safety composite endpoint of radiation treatment-related pericarditis, pneumonitis, changes in cardiac structures, function, and/or ICD function.
Six months
Overall mortality

Trial Safety

Trial Design

1 Treatment Group

Radioablation Treatment
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Stereotactic Radioablation · No Placebo Group · N/A

Radioablation Treatment
Radiation
Experimental Group · 1 Intervention: Stereotactic Radioablation · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 month period before treatment to the 6 month period after ablation with a 6 week blanking period post-treatment.

Who is running the clinical trial?

University of CalgaryLead Sponsor
706 Previous Clinical Trials
493,701 Total Patients Enrolled
Libin Cardiovascular Institute of AlbertaOTHER
3 Previous Clinical Trials
628 Total Patients Enrolled
Vikas Kuriachan, MDPrincipal InvestigatorUniversity of Calgary

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: